Global Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2019-2025

2 Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size Analysis

• 2.1 Drugs for Non-small Cell Lung Cancer Business Impact Assessment - COVID-19
  • 2.1.1 Global Drugs for Non-small Cell Lung Cancer Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Drugs for Non-small Cell Lung Cancer Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Drugs for Non-small Cell Lung Cancer Headquarters and Area Served
• 3.3 Date of Key Players Enter into Drugs for Non-small Cell Lung Cancer Market
• 3.4 Key Players Drugs for Non-small Cell Lung Cancer Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Drugs for Non-small Cell Lung Cancer Segments, By Type

• 4.1 Introduction
  • 1.4.1 Radiofrequency Ablation (RFA)
  • 1.4.2 Radiation Therapy
  • 1.4.3 Chemotherapy
  • 1.4.4 Targeted Therapies
  • 1.4.5 Immunotherapy
• 4.2 By Type, Global Drugs for Non-small Cell Lung Cancer Market Size, 2019-2021

5 Impact of Covid-19 on Drugs for Non-small Cell Lung Cancer Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals
  • 5.5.2 Clinics
  • 5.5.3 Other
• 5.2 By Application, Global Drugs for Non-small Cell Lung Cancer Market Size, 2019-2021
  • 5.2.1 By Application, Global Drugs for Non-small Cell Lung Cancer Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Bristol-Myers Squibb
  • 7.1.1 Bristol-Myers Squibb Business Overview
  • 7.1.2 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.1.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.2 GlaxoSmithKline
  • 7.2.1 GlaxoSmithKline Business Overview
  • 7.2.2 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.2.4 GlaxoSmithKline Response to COVID-19 and Related Developments
• 7.3 Menarini
  • 7.3.1 Menarini Business Overview
  • 7.3.2 Menarini Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.3.3 Menarini Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.3.4 Menarini Response to COVID-19 and Related Developments
• 7.4 Sanofi
  • 7.4.1 Sanofi Business Overview
  • 7.4.2 Sanofi Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.4.4 Sanofi Response to COVID-19 and Related Developments
• 7.5 Ziopharm Oncology
  • 7.5.1 Ziopharm Oncology Business Overview
  • 7.5.2 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.5.4 Ziopharm Oncology Response to COVID-19 and Related Developments
• 7.6 Alchemia
  • 7.6.1 Alchemia Business Overview
  • 7.6.2 Alchemia Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.6.4 Alchemia Response to COVID-19 and Related Developments
• 7.7 Amgen
  • 7.7.1 Amgen Business Overview
  • 7.7.2 Amgen Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.7.3 Amgen Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.7.4 Amgen Response to COVID-19 and Related Developments
• 7.8 Apotex
  • 7.8.1 Apotex Business Overview
  • 7.8.2 Apotex Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.8.3 Apotex Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.8.4 Apotex Response to COVID-19 and Related Developments
• 7.9 BioMarin Pharmaceutical
  • 7.9.1 BioMarin Pharmaceutical Business Overview
  • 7.9.2 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.9.4 BioMarin Pharmaceutical Response to COVID-19 and Related Developments
• 7.10 CellAct Pharma
  • 7.10.1 CellAct Pharma Business Overview
  • 7.10.2 CellAct Pharma Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.10.4 CellAct Pharma Response to COVID-19 and Related Developments
• 7.11 Cerulean Pharma
  • 7.11.1 Cerulean Pharma Business Overview
  • 7.11.2 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.11.4 Cerulean Pharma Response to COVID-19 and Related Developments
• 7.12 Cipla
  • 7.12.1 Cipla Business Overview
  • 7.12.2 Cipla Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.12.3 Cipla Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.12.4 Cipla Response to COVID-19 and Related Developments
• 7.13 Cornerstone Pharmaceuticals
  • 7.13.1 Cornerstone Pharmaceuticals Business Overview
  • 7.13.2 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.13.4 Cornerstone Pharmaceuticals Response to COVID-19 and Related Developments
• 7.14 Curis
  • 7.14.1 Curis Business Overview
  • 7.14.2 Curis Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.14.3 Curis Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.14.4 Curis Response to COVID-19 and Related Developments
• 7.15 CytRx
  • 7.15.1 CytRx Business Overview
  • 7.15.2 CytRx Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.15.3 CytRx Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.15.4 CytRx Response to COVID-19 and Related Developments
• 7.16 Eli Lilly
  • 7.16.1 Eli Lilly Business Overview
  • 7.16.2 Eli Lilly Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.16.4 Eli Lilly Response to COVID-19 and Related Developments
• 7.17 Exelixis
  • 7.17.1 Exelixis Business Overview
  • 7.17.2 Exelixis Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.17.4 Exelixis Response to COVID-19 and Related Developments
• 7.18 Fresenius Kabi
  • 7.18.1 Fresenius Kabi Business Overview
  • 7.18.2 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.18.4 Fresenius Kabi Response to COVID-19 and Related Developments
• 7.19 Genentech
  • 7.19.1 Genentech Business Overview
  • 7.19.2 Genentech Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.19.3 Genentech Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.19.4 Genentech Response to COVID-19 and Related Developments
• 7.20 Hikma Pharmaceuticals
  • 7.20.1 Hikma Pharmaceuticals Business Overview
  • 7.20.2 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.20.4 Hikma Pharmaceuticals Response to COVID-19 and Related Developments
• 7.21 Hospira
  • 7.21.1 Hospira Business Overview
  • 7.21.2 Hospira Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.21.3 Hospira Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.21.4 Hospira Response to COVID-19 and Related Developments
• 7.22 Intas Pharmaceuticals
  • 7.22.1 Intas Pharmaceuticals Business Overview
  • 7.22.2 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.22.4 Intas Pharmaceuticals Response to COVID-19 and Related Developments
• 7.23 Karyopharm Therapeutics
  • 7.23.1 Karyopharm Therapeutics Business Overview
  • 7.23.2 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.23.4 Karyopharm Therapeutics Response to COVID-19 and Related Developments
• 7.24 Kyowa Hakko Kirin
  • 7.24.1 Kyowa Hakko Kirin Business Overview
  • 7.24.2 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.24.4 Kyowa Hakko Kirin Response to COVID-19 and Related Developments
• 7.25 Ligand Pharmaceuticals
  • 7.25.1 Ligand Pharmaceuticals Business Overview
  • 7.25.2 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Quarterly Revenue, 2020
  • 7.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product Introduction
  • 7.25.4 Ligand Pharmaceuticals Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US